Crescent Biopharma, Inc. · GETTEX:C68

Crescent Biopharma, Inc. financial statements

Crescent Biopharma, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue10.8M10.0K75.0K1.16M10.2M18.5K
Cost of revenue84.0K35.2K153.3K1.03M951.6K899.3K275.1K263.5K
Gross profit10.8M-35.2K10.0K75.0K1.16M10.2M-899.3K-275.1K-263.5K18.5K
Research and development138.1M14.3M20.1M28.4M47.5M44.9M47.0M40.1M24.1M23.3M
Selling, general and administrative25.4M16.3M19.2M19.1M17.1M16.7M14.4M11.4M9.83M8.65M
Operating income-152.6M-40.0M-39.3M-47.4M-63.4M-51.5M-61.4M-51.5M-33.9M-31.9M
Depreciation and amortization84.0K35.2K153.3K207.1K264.6K270.8K279.2K275.1K263.5K190.5K
EBITDA-152.5M-40.0M-39.1M-47.2M-63.2M-51.2M-61.1M-51.2M-33.7M-31.7M
Interest expense2.19M852.0K
Income before tax-151.9M-48.5M-36.9M-46.7M-63.4M-51.0M-57.9M-48.3M-33.3M-31.8M
Income tax2.00M-3.78M3.23M
Net income-153.9M-37.9M-36.9M-46.7M-63.4M-51.0M-57.9M-48.3M-33.3M-31.8M
Earnings per share, basic-5.59-0.59-0.58-0.89-1.23-1.12-1.34-1.18-1.13-1.50
Earnings per share, diluted-0.59-0.58-0.89-1.23-1.12-1.34-1.18-1.13-1.50

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents213.2M34.8M41.8M47.9M90.3M137.0M158.2M209.9M123.9M40.0M
Short-term investments10.6K
Receivables18.0M0175.8K144.0K1.35K2.15K186.0K413.1K102.0K268.7K
Inventory-405198.8K
Current assets236.7M34.8M43.8M50.7M90.8M138.3M162.5M212.3M127.2M40.5M
Property, plant and equipment846.0K0242.4K368.8K620.7K822.9K957.2K1.11M1.06M
Total assets240.3M35.6M45.3M51.8M94.3M142.8M168.0M214.8M128.6M42.4M
Accounts payable10.00M329.3K868.1K970.2K2.11M2.09M1.44M2.66M2.65M1.57M
Current liabilities36.1M9.61M6.84M8.88M11.8M12.4M11.0M8.76M8.17M6.33M
Long-term debt37.5M
Total debt1.64M37.5M808.4K918.6K1.92M2.82M3.62M
Total liabilities37.3M47.1M6.90M8.88M12.7M14.6M13.8M9.37M8.88M7.09M
Shareholders' equity203.0M-15.5M38.4M42.9M81.6M128.2M154.2M205.5M119.7M35.3M
Shares outstanding27.6M1.02M64.4M54.4M52.3M49.0M43.5M43.2M34.4M23.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-71.5M-31.1M-34.9M-46.5M-57.5M-39.2M-52.0M-43.3M-29.8M-29.7M
Capital spending-919.0K-9.97K-21.4K-84.2K-14.9K-68.5K-144.9K-125.6K-294.1K-704.2K
Free cash flow-72.5M-31.1M-34.9M-46.5M-57.5M-39.3M-52.1M-43.5M-30.1M-30.4M
Cash from investing-72.9M20.0K-21.4K-84.2K-14.9K-68.5K-144.9K-125.6K-294.1K-704.2K
Cash from financing323.0M5.40K28.8M4.16M10.7M18.1M412.9K129.4M113.9M23.7M
Share buybacks-177.0K
Change in cash178.5M-31.1M-6.08M-42.4M-46.8M-21.2M-51.7M86.0M83.9M-6.76M